Top

Published in:

01-05-2013 | Review Article

The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients

Authors: Jean Klastersky, Marianne Paesmans

Published in: Supportive Care in Cancer | Issue 5/2013

Abstract

The Multinational Association for Supportive Care in Cancer risk index score developed, through a multinational collaboration, was published in 2000 with the aim to identify patients with chemotherapy-induced febrile neutropenia at low risk of serious medical complication development. It has been endorsed as a reliable tool since 2002 by Infectious Diseases Society of America. Ten years after, we thought worth to review its use, its characteristics in the external validations that occurred after the initial publication and also to review how the recognition of a group of patients at low risk has changed the management of febrile neutropenia. We also raise the issue of identification of high-risk patients that remains a challenge today.

Bodey GP, Buckley M, Sathe YS et al (1996) Quantitative relationship between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328–340

Schimpff S, Satterlee W, Young VM et al (1971) Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 284:161–165CrossRef

Klastersky J (1983) Empiric treatment of infections in neutropenic patients with cancer. Rev Infect Dis 5:S21–S23PubMedCrossRef

The EORTC International Antimicrobial Therapy Cooperative Group (1978) Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 317:1692–1698

Talcott JA, Siegel RD, Finberg R et al (1992) Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 10:316–322PubMed

Talcott JA, Whalen A, Clark J et al (1994) Home antibiotic-therapy for low-risk cancer patients with fever and neutropenia-a pilot-study of 30 patients based on a validated prediction rule. J Clin Oncol 12:107–114PubMed

Kern WV, Cometta A, De Bock R et al (1999) Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 314:312–318CrossRef

Freifeld A, Marchigiani D, Walsh T et al (1999) A double blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 341:305–3011PubMedCrossRef

Klastersky J, Paesmans M, Rubenstein EB et al (2000) The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038–3051PubMed

10.

Naurois J, Novitzky-Basso I, Gill JM et al (2010) Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol 21:252–256CrossRef

11.

Hughes WT, Amstrong D, Bodey GP et al (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751PubMedCrossRef

12.

Freifeld A, Bow E, Sepkowitz K et al (2011) Executive summary: clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by infectious diseases society of America. Clin Infect Dis 52:e56–e93PubMedCrossRef

13.

Uys A, Rapoport B, Anderson R (2004) Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk index score. Support Care Cancer 12:555–560PubMedCrossRef

14.

Cherif H, Johansson E, Björkholm M et al (2006) The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. Haematologica 91:215–222PubMed

15.

Baskaran ND, Gan GG, Adeeba K (2008) Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients. Ann Hematol 87:563–569PubMedCrossRef

16.

Pun Hui E, Leung KS, Poon T et al (2011) Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network. Support Care Cancer 19:1625–1635CrossRef

17.

Carmona-Bayonas A, Gómez J, González-Billalabeitia E et al (2011) Prognostic evaluation of febrile neutropaenia in apparently stable adult cancer patient. Br J Cancer 105:612–617PubMedCrossRef

18.

Philips R, Wade R, Lehrnbecher T et al (2012) Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer. BMC Med 10:6CrossRef

19.

Paesmans M, Klastersky J, Maertens J et al (2011) Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter? Support Care Cancer 19:1001–1008PubMedCrossRef

20.

Furno P, Bucaneve G, Del Favero A (2002) Monotherapy or aminoglycoside containing combinations for empirical antibiotic treatment of febrile neutropenia patients: a meta-analysis. Lancet 2:231–243

21.

Kridel R, Van Delden C, Calandra T et al (2008) Antibiothérapie empirique lors de neutropénie febrile. Rev Med Suisse 4:914–919PubMed

22.

Mebis J, Goossens H, Berneman ZN (2010) Antibiotic management of febrile neutropenia: current developments and future directions. J Chemother 22:5–12PubMed

23.

Event C, Taillade L, Spano JP et al (2010) Neutropénie fébrile chez le patient adulte atteint de tumeur solide: revue de la littérature pour une gestion rationnelle et optimale. Bull Cancer 97:547–557

24.

Tam CS, O’Reilly M, Andresen D et al (2011) Use of empiric antimicrobial therapy in neutropenic fever. Intern Med J 41:90–101PubMedCrossRef

25.

Rolston K, Frisbee-Hume S, Patel S et al (2010) Oral moxifloxacin for outpatients treatment of low-risk, febrile neutropenic patients. Support Care Cancer 18:89–94PubMedCrossRef

26.

Zuckermann J, Moreira L, Stoll P (2008) Compliance with a critical pathway for the management of febrile neutropenia and impact on clinical outcomes. Ann Hematol 87:139–145PubMedCrossRef

27.

Sebban C, Dussart S, Fuhrmann C et al (2008) Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge. Support Care Cancer 16:1017–1023PubMedCrossRef

28.

Innes HE, Smith DB, O’Reilly SM et al (2003) Oral antibiotics with early hospital discharge compared with in-patients intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomized controlled single centre study. Br J Cancer 89:43–49PubMedCrossRef

29.

Innes H, Lim S, Hall A et al (2008) Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice. Support Care Cancer 16:485–4941PubMedCrossRef

30.

Klastersky J, Paesmans M, Georgala A et al (2006) Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 24:4129–4134PubMedCrossRef

31.

Brack E, Bodmer N, Simon A et al (2012) First-day step-down to oral outpatient treatment versus continued standard treatment in children with cancer and low-risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study. Pediatr Blood Cancer 59(3):423–430. doi:10.1002/pbc.24076 PubMedCrossRef

32.

Carstensen M, Sorensen JB (2008) Outpatient management of febrile neutropenia: time to revise the present treatment strategy. J Support Oncol 6:199–208PubMed

33.

Teuffel O, Ethier MC, Alibhal SM et al (2011) Outpatient management of cancer patients with febrile neutropenia: a systematic review and meta-analysis. Ann Oncol 22:2358–2365PubMedCrossRef

34.

Teuffel E, Amir, Alibhai S et al (2011) Cost-effectiveness of outpatient treatment for febrile neutropaenia in adult cancer patients. B JCancer 104:1377–1383CrossRef

35.

Elting L, Lu C, Escalante C et al (2008) Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 26:606–611PubMedCrossRef

36.

Talcott J, Yeap B, Clark J et al (2011) Safety of early discharge for low-risk patients with febrile neutropenia: a multicenter randomized controlled trial. J Clin Oncol 29:3977–3988PubMedCrossRef

37.

Hendricks A, Trice Loggers E, Talcott J (2011) Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. J Clin Oncol 29:3984–3988PubMedCrossRef

38.

Teuffel O, Cheng S, Ethier M et al (2012) Health-related quality of life anticipated with different management strategies for febrile neutropenia in adult cancer patients. Support Care Cancer 20(11):2755–2764PubMedCrossRef

39.

Diorio C, Martino J, Boydell K et al (2011) Parental perspectives on inpatient versus outpatient management of pediatric febrile neutropenia. J Pediatr Oncol Nurs 28:355–362PubMedCrossRef

40.

Manji A, Beyene J, Dupuis R et al (2012) Outpatient and oral antibiotic management of low-risk febrile neutropenia are effective in children—a systematic review of prospective trials. Support Care Cancer 20:1135–1145PubMedCrossRef

41.

Sung L, Alibhai S, Ethier MC et al (2012) Discrete choice experiment produced estimates of acceptable risks of therapeutic options in cancer patients with febrile neutropenia. J Clin Epidemiol 65:627–634PubMedCrossRef

42.

Freifeld A, Sankaranarayanan J, Ullrich F et al (2008) Clinical practice patterns of managing low-risk adult febrile neutropenia during cancer chemotherapy in the USA. Support Care Cancer 16:181–191PubMedCrossRef

43.

Rubenstein EB, Rolston K, Benjamin RS et al (1993) Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 71:3640–3646PubMedCrossRef

44.

Klastersky J, Ameye L, Maertens et al (2007) Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 30(Suppl 1):S51–S59PubMedCrossRef

45.

Blot F, Nitenberg G (2004) Patients neutropéniques fébriles à bas et haut risques. Presse Med 33:473–479CrossRef

46.

Sammut S, Mazhar D (2012) Management of febrile neutropenia in an acute oncology service. Q J Med 105:327–336CrossRef

47.

André S, Taboulet P, Elie C (2010) Febrile neutropenia in French emergency departments: results of a prospective multicentre survey. Crit Care 14:R68PubMedCrossRef

48.

Lim C, Bawden J, Wing A et al (2012) Febrile neutropenia in EDs: the role of an electronic clinical practice guideline. Am J Emerg Med 30(1):5, 11, 11.e1–5PubMedCrossRef

49.

Rivers E, Nguyen B, Havstad S et al (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368–1377PubMedCrossRef

50.

Ahn S, Lee YS, Chun YH et al (2011) Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia. Support Care Cancer 19:1151–1158PubMedCrossRef

51.

Kim D, Lee YS, Ahn S et al (2011) The usefulness of procalcitonin and C-reactive protein as early diagnostic markers of bacteremia in cancer patients with febrile neutropenia. Cancer Res Treat 43:176–180PubMedCrossRef

52.

Uys A, Rapoport B, Meyer P et al (2007) Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1β, -6 and -10. Eur J Cancer Care (Engl) 16:475–483CrossRef

53.

Mato A, Luger S, Heitjan D et al (2010) Elevation in serum lactate at the time of febrile neutropenia (FN) in hemodynamically-stable patients with hematologic malignancies (HM) is associated with the development of septic shock within 48 h. Cancer Biol Ther 9:585–589PubMedCrossRef

54.

Jeddi R, Zarrouk M, Benabdennebi Y et al (2007) Predictive factors of septic shock and mortality in neutropenic patients. Hematology 12:543–548CrossRef

55.

Shaikh AJ, Bawany SA, Masood N et al (2011) Incidence and impact of baseline electrolyte abnormalities in patients admitted with chemotherapy induced febrile neutropenia. J Cancer 2:62–66PubMedCrossRef

56.

Nakagawa Y, Suzuki K, Masaoka T (2009) Evaluation of the risk factors for febrile neutropenia associated with hematological malignancy. J Infect Chemother 15:174–179PubMedCrossRef

57.

Park Y, Kim D, Park S et al (2010) The suggestion of a risk stratification system for febrile neutropenia in patients with hematologic disease. Leuk Res 34:294–300PubMedCrossRef

58.

De Souza VL, Serufo JC, da Costa Rocha MO et al (2008) Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer 16:841–846CrossRef

59.

Eun Ha Y, Song JH, Kang WK et al (2011) Clinical factors predicting bacteremia in low-risk febrile neutropenia after anti-cancer chemotherapy. Support Care Cancer 19:1761–1767CrossRef

60.

Lamoth F, Jaton K, Prod’hom G et al (2010) Multiplex blood PCR in combination with blood cultures for improvement of microbiological documentation of infection in febrile neutropenia. J Clin Microbiol 48:3510–3516PubMedCrossRef

61.

Vänskä M, Koivula I, Hämäläinen S et al (2011) High pentraxin 3 level predicts septic shock and bacteremia at the onset of febrile neutropenia after intensive chemotherapy of hematologic patients. Haematologica 96:1385–1389PubMedCrossRef

62.

Lyman G, Kuderer N, Crawford B et al (2011) Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 117:1917–1927PubMedCrossRef

63.

Moreau M, Klasterky J, Schwarzbold A et al (2009) A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies. Ann Oncol 20:513–519PubMedCrossRef

64.

Lalami Y, Paesmans M, Muanza F et al (2006) Can we predict the duration of chemotherapy-induced neutropenia in febrile neutropenic patients, focusing on regimen-specific risk factors? A retrospective analysis. Ann Oncol 17:507–514PubMedCrossRef

65.

Aapro MS, Cameron DA, Pettengell R et al (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumors. Eur J Cancer 42:2433–2453PubMedCrossRef

66.

Dale C (2009) Advances in the treatment of neutropenia. Curr Opin Support Palliat Care 3:207–212PubMedCrossRef

67.

Cooper K, Madan J, Whyte S et al (2011) Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 11:404PubMedCrossRef

68.

Klastersky J, Georgala A, Ameye L et al (2010) Febrile neutropenia (FN) in patients with solid tumors (St): is the risk of complications affected by the type of chemotherapy? Support Care Cancer 18:S67–S220

69.

Klastersky J, Awada A, Aoun M et al (2009) Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended? Curr Opin Oncol 21:297–302PubMedCrossRef

70.

Papaldo P, López M, Marolla P et al (2005) Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol 23:6908–6918PubMedCrossRef

Title: The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients
Authors: Jean Klastersky
Marianne Paesmans
Publication date: 01-05-2013
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 5/2013
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-013-1758-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2013

Advance care planning among Colombian, Mexican, and Puerto Rican women with a cancer diagnosis

Validation of the Chinese version of the Resilience Scale and its cutoff score for detecting low resilience in Chinese cancer patients

Antioxidant supplementation has a positive effect on oxidative stress and hematological toxicity during oncology treatment in cervical cancer patients

Efficacy of prophylactic lamivudine to prevent hepatitis B virus reactivation in B-cell lymphoma treated with rituximab-containing chemotherapy

Validation of the revised Bakas Caregiving Outcomes Scale in Greek caregivers of patients with advanced cancer receiving palliative radiotherapy

Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations

Keynote webinar | Spotlight on antibody–drug conjugates in cancer